Photo Source: Unsplash
Researchers from Einstein Healthcare Network in Philadelphia conducted a nationwide retrospective study using the TriNetX database from 83 large healthcare organizations across multiple countries. The study analyzed 10 years of data (January 2015 to December 2024) and included patients over 18 years old with psoriatic arthritis.
The researchers identified 4,104 psoriatic arthritis patients taking GLP-1 receptor agonists (semaglutide, liraglutide, exenatide, lixisenatide) and 86,432 psoriatic arthritis patients not taking these medications. After propensity score matching to account for demographics, diagnoses, and medication use, patients taking GLP-1 medications showed a lower risk of developing major adverse cardiovascular events and had reduced mortality compared to those not using GLP-1 drugs. The mortality hazard ratio was only 0.3 in the control group.
According to previously published research, GLP-1 receptor agonists have various effects on patient health. Beyond weight loss and improved glycemic control in type 2 diabetes, these include lower blood pressure and reduced cardiovascular risk, decreased fatty liver infiltration in non-alcoholic fatty liver disease, and effects on the reproductive system.
GLP-1 therapy is available in Russia, where nine medications are registered, both brand-name and generic versions. These include liraglutide, semaglutide, exenatide, lixisenatide, dulaglutide, albiglutide, and others. According to RNC Pharma, sales of these medications for obesity treatment in Russia reached $231.5 million in 2024 (compared to $125.3 million in 2022), and for January–April 2025, this figure already exceeded $129.2 million. Market leaders are semaglutide generics from manufacturers Geropharm and Promomed.